Literature DB >> 29559715

The controversy of using PGA to define remission in RA.

Lilian H D van Tuyl1, Maarten Boers2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29559715     DOI： 10.1038/nrrheum.2018.36

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  8 in total

1.  Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.

Authors:  D M van der Heijde; M A van 't Hof; P L van Riel; L A Theunisse; E W Lubberts; M A van Leeuwen; M H van Rijswijk; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1990-11       Impact factor: 19.103

2.  RAID: a valid tool to quantify the impact of rheumatoid arthritis. But what impact will it have on the core set for trials?

Authors:  Maarten Boers
Journal:  Ann Rheum Dis       Date:  2011-04-05       Impact factor: 19.103

3.  Rheumatoid arthritis: Remission - keeping the patient experience front and centre.

Authors:  Lilian H D van Tuyl; Maarten Boers
Journal:  Nat Rev Rheumatol       Date:  2017-08-31       Impact factor: 20.543

4.  World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.

Authors:  M Boers; P Tugwell; D T Felson; P L van Riel; J R Kirwan; J P Edmonds; J S Smolen; N Khaltaev; K D Muirden
Journal:  J Rheumatol Suppl       Date:  1994-09

Review 5.  Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. OMERACT Committee.

Authors:  P Tugwell; M Boers
Journal:  J Rheumatol       Date:  1993-03       Impact factor: 4.666

6.  American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

Authors:  David T Felson; Josef S Smolen; George Wells; Bin Zhang; Lilian H D van Tuyl; Julia Funovits; Daniel Aletaha; Cornelia F Allaart; Joan Bathon; Stefano Bombardieri; Peter Brooks; Andrew Brown; Marco Matucci-Cerinic; Hyon Choi; Bernard Combe; Maarten de Wit; Maxime Dougados; Paul Emery; Daniel Furst; Juan Gomez-Reino; Gillian Hawker; Edward Keystone; Dinesh Khanna; John Kirwan; Tore K Kvien; Robert Landewé; Joachim Listing; Kaleb Michaud; Emilio Martin-Mola; Pamela Montie; Theodore Pincus; Pamela Richards; Jeffrey N Siegel; Lee S Simon; Tuulikki Sokka; Vibeke Strand; Peter Tugwell; Alan Tyndall; Desirée van der Heijde; Suzan Verstappen; Barbara White; Frederick Wolfe; Angela Zink; Maarten Boers
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

7.  Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change.

Authors:  Ricardo J O Ferreira; Cátia Duarte; Mwidimi Ndosi; Maarten de Wit; Laure Gossec; J A P da Silva
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-01-30       Impact factor: 4.794

8.  The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

Authors:  D T Felson; J J Anderson; M Boers; C Bombardier; M Chernoff; B Fried; D Furst; C Goldsmith; S Kieszak; R Lightfoot
Journal:  Arthritis Rheum       Date:  1993-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.